Clearmind Medicine Inc is a biotechnology company focused on developing innovative therapeutics aimed at treating mental health disorders
The company leverages its expertise in psychedelic research to create novel compounds that can address conditions such as depression, anxiety, and addiction. By combining advanced scientific approaches with an emphasis on safety and efficacy, Clearmind aims to revolutionize the way mental health issues are treated, ultimately improving patient outcomes and quality of life. Their commitment to rigorous clinical trials and research positions them at the forefront of the emerging field of psychedelic medicine.
TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of a patent application in Mexico for the innovative combination of 3,4-Methylenedioxymethamphetamine (MDMA) with N-Acylethanolamines.
Vancouver, Canada, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces today a patent publication by the Instituto Mexicano de la Propriedad Industrial (IMPI), the National Mexico Patent Office. The patent refers to the Company’s innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on January 6, 2025 (the “Meeting”), as set out in the Company’s Management Information Circular dated December 1, 2024, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at five members, the election of directors of the Company for the ensuing year, to appoint Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, as auditor of the Company, a resolution to establish and approve an omnibus equity incentive plan and a resolution allowing the directors, if they deem such an action to be in the best interest of shareholders, effect a consolidation (the “Consolidation”) of the common shares in the capital of the Company (the “Shares”) on the basis of fifty (50) pre-Consolidation Shares for one (1) post-Consolidation Share, or such other lesser consolidation ratio as determined by the Company’s board of directors.
Vancouver, Canada, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a European patent application with the European Patent office for its innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, the publication of a European patent application submitted by Clearmind under the European Patent Office for innovative combination therapy of MEAI and N-Acylethanolamines, to binge behavior including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
Vancouver, Canada, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval from the Macau International Intellectual Property Office.
Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD).
Vancouver, Canada, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced the publication of its patent application under the international Patent Cooperation Treaty (“PCT”) for innovative combinations of Ketamine and N-Acylethanolamines.
Clearmind Medicine secures a U.S. patent for its MEAI-based binge behavior treatment, marking a significant advancement in addressing Alcohol Use Disorder.
Vancouver, Canada, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received a new patent approval from the United States Patent and Trademark Office, marking another significant advancement in its proprietary MEAI-based binge behavior regulator program.
Vancouver, Canada, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty (“PCT”) as part of the company’s ongoing collaboration with the with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”) pursuant to the exclusive licensing agreement that the Company entered into with Yissum.
Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The study was meticulously conducted by a team of experts led by Prof. Joseph Tam, head of the Obesity and Metabolism Laboratory at the School of Pharmacy in the Hebrew University of Jerusalem.
